COSENTYX (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
COSENTYX
Date registered
Evaluation commenced
Decision date
Approval time
189 (255 working days)
Active ingredients
Secukinumab
Registration type
EOI
Indication
Hidradenitis Suppurativa (HS)
COSENTYX is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.